Exclusivity Obligation. During the Term of this Agreement, ILDONG shall not, and shall cause each of its Affiliates to not, conduct any activity, either on its own, or with, for the benefit of, or sponsored by, any Third Party, that, in any case, involves the research, development or commercialization of any other anti CD 20 monoclonal antibody, or any compound that embodies or is derived from any anti CD 20 monoclonal antibody, for use in the Field that is competitive with or adversely affects the Development or Commercialization of any of the Compounds or Products, except hereunder in connection with the research, Development and/or the Commercialization of the Compounds and Products. Notwithstanding the foregoing, at ILDONG’s request, SUBLICENSOR may allow ILDONG to Develop and Commercialize all combinations with the Compounds and Products which would be benefit in improving the Development and/or the Commercialization of the Compounds and Products, such consent to not be unreasonably withheld.
Exclusivity Obligation. Unless expressly agreed to by Customer in writing on a case-by-case basis, Manufacturer will not, during the Exclusivity Period set forth in Exhibit E, design or manufacture any Conflicting Product (as defined below) for any other customer, except Existing Customers (as defined below), in [*]. This Section does not expand in any way the scope of Manufacturer’s limited license rights with respect to the Product Designs, as granted in Section 7.3 above.
Exclusivity Obligation. The National Gallery in Prague undertakes with respect to Xxxx & Bülow Versicherungsmakler GmbH that in the event of any outgoing loan of items of artistic, historical value or collector's interest managed or disposed of by the National Gallery in Prague to a third party outside the territory of the Czech Republic, such outgoing loan shall be granted by the National Gallery in Prague only under the condition that the borrower jakožto půjčitelem, výslovně a bez jakýchkoliv podmínek zaváže sjednat pojištění konkrétního předmětu výpůjčky mimo území České republiky výlučně prostřednictvím Xxxx & Bülow Versicherungsmakler GmbH. V případě závazku Národní galerie v Praze sjednaného v tomto odstavci platí, že jde o reciproční kompenzační závazek, smluvně podmíněný obdobným závazkem Xxxx & Bülow Versicherungsmakler GmbH sjednaným v odst.
Exclusivity Obligation. During the Term with respect to each Product, Arcturus shall not, and shall ensure that its Affiliates do not, and CureVac shall not, and shall ensure that its Affiliates do not, directly or indirectly, alone or with or through any Third Party, clinically develop or commercialize any Competing Product to such Product in the Territory.
Exclusivity Obligation. During the Term, Licensee will work exclusively with Mascoma in the Field with respect to the Mascoma Process, Mascoma Process Validated Improvements, Organisms and Organism Validated Improvements (other than as permitted below) at the Kinross Facility. Notwithstanding the foregoing, without limiting Mascoma’s rights to the Process-Related IP or Field-Related IP (each as defined in Section 6), Licensee will have the right to incorporate non-Mascoma Third Party technologies at the Kinross Facility (for PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. TECHNOLOGY LICENSE AND SUPPLY AGREEMENT example and not by way of limitation, Andritz pre-treatment technology or the conversion of lignin to saleable products), provided that at the time of such incorporation, such Third Party technology does not circumvent the Mascoma Process, Mascoma Process Validated Improvements, Organisms or Organism Validated Improvements, as applicable.
Exclusivity Obligation. During the Term, Licensee will work exclusively with Mascoma in the Field with respect to the Mascoma Process, Mascoma Process Validated Improvements, Organisms and Organism Validated Improvements (other than as permitted below) at the Kinross Facility. Notwithstanding the foregoing, without limiting Mascoma’s rights to the Process-Related IP or Field-Related IP (each as defined in Section 6), Licensee will have the right to incorporate non-Mascoma Third Party technologies at the Kinross Facility PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. TECHNOLOGY LICENSE AND SUPPLY AGREEMENT [***], provided that at the time of such incorporation, such Third Party technology does not circumvent the Mascoma Process, Mascoma Process Validated Improvements, Organisms or Organism Validated Improvements, as applicable. [***] [***] [***] PORTIONS OF THIS EXHIBIT WERE OMITTED AND HAVE BEEN FILED SEPARATELY WITH THE SECRETARY OF THE COMMISSION PURSUANT TO AN APPLICATION FOR CONFIDENTIAL TREATMENT UNDER RULE 406 OF THE SECURITIES ACT; [***] DENOTES OMISSIONS. TECHNOLOGY LICENSE AND SUPPLY AGREEMENT
Exclusivity Obligation. (a) It is understood between the parties that (i) Seller has worked with Buyer over the past eight years in the supply of the Product to assist Buyer in the development of Buyer's new proprietary positron emission tomography medical scanning equipment (the "PET Scanner"), (ii) Buyer has made a significant capital investment in its crystal growth operations for the production of scintillators using the Product and recently commenced commercial production of the PET Scanner, (iii) Buyer desires to be assured of a guaranteed source of supply of the Product which constitutes a key raw material needed in the continued full scale production of the PET Scanner, and (iv) Seller has made a significant capital investment to increase its production capacity of Virgin Product to meet Buyer's anticipated demand under this Agreement, and further, in reliance on sales of Recycled Product under this Agreement, has made an additional capital investment to purchase and install a new production unit to recycle Scrap Product into Recycled Product for supply to Buyer. Furthermore, Seller understands, based on Buyer's representation set forth below in section 12(b), that there are currently no other manufacturers of medical imaging equipment for human studies engaged in the commercial production of lutetium oxide-based scintillation crystals. For the foregoing reasons, and subject to Section 4 and Exhibit C on quantities, Seller agrees that, during the Initial Term of this Agreement, Seller will not, directly or indirectly, make commercial sales to any third party other than Buyer of Virgin Product, Recycled Product, lutetium concentrates or lutetium based products regardless of form or enrichment levels (the * Omitted information is the subject of a request for confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934 and has been filed separately with the Securities and Exchange Commission.
Exclusivity Obligation. During the Exclusivity Period with respect to each Collaboration Target, neither Party will, and will not cause its Affiliates to, by itself or themselves, or in collaboration with or on behalf of any Third Party, [***] in the Territory, a Competitive Product, in each case, other [***]. Notwithstanding the foregoing, nothing in this Agreement shall prohibit either Party or its Affiliates from: (a) [***] (b) [***] (a “Third Party Competitive Product”) [***]. Without limitation of the foregoing, during the Term with respect to each Collaboration Target, [***]. If an [***] occurs, then during the remainder of the Exclusivity Period for the Collaboration Target subject thereto, [***] shall not initiate (or have initiated) any new [***] activities to [***] Directed To such Collaboration Target.
Exclusivity Obligation. Subject to Section 2.5.5(a)(C) ([**]), Section 2.5.5(b)(B) ([**]), and Section 2.6.2 ([**]), Roche and its Affiliates will not, directly or indirectly by itself or in collaboration with a Third Party, perform any Clinical Trials that relate to, or Commercialize, any Gene Therapy Product, Gene Editing-Product, or antisense oligonucleotide product that targets the dystrophin gene to induce exon skipping, in each case, for the treatment, prevention, cure or amelioration of DMD (“Competitive Product”) during the time period beginning on the Execution Date (to the extent permissible under Applicable Law) and continuing until the date that is five years following the Effective Date (the “Exclusivity Period”); provided that on an Option Product-by-Option Product basis:
